Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330070 · ClinicalTrials.gov registry record · Phase 2
Control of Asthma Patients Symptomatic on Inhaled Corticosteroids
A Phase 2 study of Asthma, sponsored by Inflazyme Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 8
- Study locations
NCT00330070: Completed Phase 2 study of Asthma, sponsored by Inflazyme Pharmaceuticals.
NCT00330070 is a Phase 2 study of Asthma that has completed, run by Inflazyme Pharmaceuticals. The registered enrollment target is 200 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00330070, a Phase 2 study of Asthma, has completed, sponsored by Inflazyme Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of the study is to determine whether IPL512,602 is safe and effective for the treatment of asthma symptoms in patients who remain symptomatic on a background therapy of inhaled corticosteroids.
Conditions Studied
Interventions
- DRUG IPL512,602 20 mg once daily
- DRUG IPL512,602 Matching Placebo once daily
Study Locations (8)
California
- West Coast Clinical Trials - Long Beach
- Allergy Research Foundation, Inc. - Los Angeles
- Asthma Medical Group & Resarch - San Diego
- San Jose Clinical Research - San Jose
Oregon
- Clinical Research Institute of South Oregaon - Medford
- Allergy Associates Research Center - Portland
Massachusetts
- Northeast Medical Research Associates, Inc - No. Dartmouth
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330070
The ClinicalTrials.gov registry entry for NCT00330070 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The listed sponsor is Inflazyme Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which IPL512,602 20 mg once daily is the first listed.
NCT00330070 reports 8 study locations spanning 4 distinct geographic areas - top geographies include California, Oregon, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00330070 about?
NCT00330070 is a clinical study titled "Control of Asthma Patients Symptomatic on Inhaled Corticosteroids". The purpose of the study is to determine whether IPL512,602 is safe and effective for the treatment of asthma symptoms in patients who remain symptomatic on a background therapy of inhaled corticosteroids.
What is the current status of trial NCT00330070?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2006-05. Estimated completion is 2007-01.
What conditions does trial NCT00330070 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00330070?
The interventions under investigation include: IPL512,602 20 mg once daily (DRUG), IPL512,602 Matching Placebo once daily (DRUG).
Who is sponsoring clinical trial NCT00330070?
This trial is sponsored by Inflazyme Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00330070 being conducted?
This trial has 8 study locations across California, Massachusetts, Oregon, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.